탈세포화된 폐 조각으로 제조된 조작된 폐 조직

Executive Industry Relevance

Engineered lung tissues (ELTs) derived from decellularized precision-cut lung slices provide a physiologically relevant 3D model for studying alveolar biology, enabling mechanistic de-risking of pulmonary targets and pathways. This platform supports target validation by recapitulating native lung extracellular matrix and multi-cellular interactions, improving predictive confidence in early discovery. The system facilitates translational continuity from discovery through preclinical evaluation by maintaining alveolar epithelial type 2 cell function in a disease-relevant system.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses within a native-like alveolar microenvironment comprising epithelium, mesenchyme, and endothelium.
• Operational Value: Supports functional target validation through recellularization of acellular scaffolds with primary lung cells, reducing mechanistic ambiguity.
• Scientific Value: Enhances predictive confidence by modeling cell-cell and cell-matrix interactions within the alveolus, informing pathway clarification and portfolio triage.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems with preserved alveolar architecture for downstream compound screening and biomarker assessment.
• Operational Value: Addresses assay standardization and reproducibility through cassette-based handling and parallel seeding of multiple ELTs.
• Scientific Value: Enables reliable compound evaluation by providing quantitative readouts via phase contrast microscopy, immunofluorescence, and hemocytometer-based cell counting.

Translational & Preclinical Research

• Scientific Value: Supports disease relevance through alveolar-like structures containing AEC2s, fibroblasts, and endothelial cells within native-like ECM.
• Operational Value: Ensures translational continuity by maintaining AEC2 phenotype and function for at least 7 days in serum-free, chemically-defined medium.
• Scientific Value: Facilitates risk-adjusted advancement decisions by modeling biochemical signals regulating AEC2s and their niche, enabling mechanistic de-risking.

Pipeline & Workflow Integration

The ELT platform integrates into the discovery continuum from target validation through lead identification to preclinical studies, supported by its ability to model alveolar structure and function.

• Discovery Biology: Supports hypothesis testing and pathway clarification by enabling studies of cell-cell and cell-matrix interactions within the alveolus.
• Screening: Delivers assay readiness and reproducibility through standardized cassette handling and parallel tissue preparation.
• Analytics: Provides quantitative measurements including phase contrast microscopy for repopulation monitoring, immunofluorescence for cell-specific markers (ABCA3, CD31, pro-collagen I), and hemocytometer-based counting of AEC2s and fibroblasts.
• Translational Research: Connects discovery to preclinical continuity through preserved alveolar septa repopulation and sustained AEC2 marker expression (SPB, ABCA3) over culture duration.
• Enterprise Reuse: Functions as a reusable platform adaptable to various tissue scaffolds, cell types, and culture media, supporting scalable workflows across projects.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence through mechanistic de-risking of alveolar targets and reduction of biological uncertainty in pulmonary programs.
• Operational Value: Standardization, reproducibility, and scalability via cassette system and parallel processing of multiple ELTs.
• Strategic Value: Improved go/no-go decisions by enabling early assessment of target engagement in a native-like lung microenvironment.
• Portfolio Impact: Risk-adjusted prioritization based on functional readouts of AEC2 proliferation, differentiation, and niche interactions.

Implementation Considerations

• Requires expertise in tissue handling, primary cell culture, and decellularization protocols.
• Dependent on instrumentation for precision slicing (450 µm thickness), orbital shaking (30 RPM), and phase contrast microscopy (5X magnification).
• Necessitates cross-team standardization for cassette preparation, sterile seeding, and medium exchange procedures.
• Involves adaptation considerations when applying the system to human or disease-model lung scaffolds.
• Practical limitations include variability in recellularization patterns and dependence on optimal cell seeding density and medium conditions.

Biopharma FAQs